Graham, J, Wells, J C, Dudani, S, Gan, C L, Donskov, F, Lee, J L, Kollmannsberger, C K, Meza, L, Beuselinck, B, Hansen, A, North, S A, Bjarnason, G A, Sayegh, N, Kanesvaran, R, Wood, L A, Hotte, S J, McKay, R R, Choueiri, T K & Heng, D Y C 2022, ' Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy ', European Journal of Cancer, vol. 171, pp. 124-132 . https://doi.org/10.1016/j.ejca.2022.05.002
Araujo, D V, Wells, J C, Hansen, A R, Dizman, N, Pal, S K, Beuselinck, B, Donskov, F, Gan, C L, Yan, F, Tran, B, Kollmannsberger, C K, de Velasco, G, Yuasa, T, Reaume, M N, Ernst, D S, Powles, T, Bjarnason, G A, Choueiri, T K, Heng, D Y C & Dudani, S 2021, ' Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis ', Journal of Geriatric Oncology, vol. 12, no. 5, pp. 820-826 . https://doi.org/10.1016/j.jgo.2021.02.022
Cancer Medicine Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021) Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717
Savard, M F, Wells, J C, Graham, J, Dudani, S, Steinharter, J A, McGregor, B A, Donskov, F, Bjarnason, G A, Vaishampayan, U N, Hansen, A R, Iafolla, M A J, Zanotti, G, Huynh, L, Chang, R, Duh, M S & Heng, D Y C 2020, ' Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group ', Oncologist, vol. 25, no. 5, pp. 422-430 . https://doi.org/10.1634/theoncologist.2019-0605 Oncologist